Assessment of characteristics and treatment patterns of adult patients with acquired aplastic anemia in Turkiye (PLANE-TR)

ANNALS OF HEMATOLOGY, cilt.105, sa.130, ss.1-9, 2026 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 105 Sayı: 130
Basım Tarihi: 2026
Doi Numarası: 10.1007/s00277-026-06871-y
Dergi Adı: ANNALS OF HEMATOLOGY
Derginin Tarandığı İndeksler: Scopus, Science Citation Index Expanded (SCI-EXPANDED), BIOSIS, CINAHL, EMBASE, MEDLINE
Sayfa Sayıları: ss.1-9
Eskişehir Osmangazi Üniversitesi Adresli: Evet

Acquired aplastic anemia (AA) is a rare blood disorder causing hypocellular bone marrow due to immune damage to

hematopoietic stem cells, leading to low blood cell counts. This study investigates the demographics, treatment patterns,

and clinical outcomes of AA in Turkiye. In this non-interventional, retrospective descriptive study, data of 274 patients

(Female/Male: 4/5) diagnosed with AA between September 1, 2011, and September 1, 2021, were collected from 16 cen-

ters. Severe and very severe AA was diagnosed in 72% and 27.7% of patients, respectively. The mean time from diagnosis

to first treatment was 119

287 days, while time to hematopoietic stem cell transplantation (HSCT) was 212

321 days,

and to Anti-Thymocyte Globulin (ATG) was 87

242.5 days. The mean time to response after first-line and second-line

treatment was 172.9

264.6 days and 191.9

211.9 days, respectively. The mean overall survival of patients with AA was

3.56

3.12 years, with a 5-year overall survival rate of 72.6%. HSCT and other initial treatments led to full or partial

remission for most patients, improving survival rates for over half of them. The study observed comparable patterns to

previous studies, providing vital insights into Turkiye’s acquired AA treatment landscape.